ArticleJournal of thoracic disease2025
Interleukin-6-to-lymphocyte count ratio in the prognosis of moderate-to-severe acute respiratory distress syndrome supported by venovenous extracorporeal membrane oxygenation: a single-center retrospective study.
Article in Journal of thoracic disease, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Inflammation and immune status are essential in acute respiratory distress syndrome (ARDS), wherein excessive inflammation with severe immunosuppression is associated with a poor prognosis. This study investigated the interleukin-6 (IL-6) and lymphocyte count (Lym) in patients with moderate-to-severe ARDS supported by venovenous extracorporeal membrane oxygenation (VV ECMO), as well as their relationship with prognosis, providing new insights for clinical prognosis evaluation. Methods: A single-center, retrospective cohort study was conducted using data collected between March 2022 and July 2024. A total of 117 patients with moderate-severe ARDS with VV ECMO support were enrolled in this study. The observational clinical outcome was intensive care unit (ICU) 28-day mortality. Cox proportional hazard regression analysis was used to determine the potential prognostic factors for ICU 28-day mortality. Receiver operating characteristic (ROC) curve analysis was used to evaluate and compare the prognostic factors for 28-day mortality. Kaplan-Meier survival curves were generated to compare the mortality, with log-rank tests used to analyze differences. Results: Of 117 patients, 60 died in the ICU within 28 days. The survivors had higher Sequential Organ Failure Assessment (SOFA) scores, IL-6, and peak airway pressure (Ppeak), and had lower Lym. According to univariable Cox analysis, baseline SOFA score [hazard ratio (HR): 1.09, 95% confidence interval (CI) 1.02-1.18; P=0.02], baseline norepinephrine (NE) dose (HR: 2.13, 95% CI: 1.30-3.48; P=0.003), baseline lactate (HR: 1.13, 95% CI: 1.07-1.19; P<0.001), baseline static lung compliance (C Conclusions: IL-6/Lym may be an independent protective factor for predicting ICU 28-day mortality in patients with moderate-to-severe ARDS supported with VV ECMO. The conclusions of the study need to be further confirmed by a multicenter prospective study.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.